ReviewWorld journal of gastroenterology2012
Colitis associated with biological agents.
Review in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 72 citations in OpenAlex.
- Gastrointestinal adverse events related to monoclonal antibodies: A comprehensive evaluation of data from the FDA Adverse Event Reporting System database.Indian journal of pharmacology · 2026Article
- A case of seropositive autoimmune autonomic ganglionopathy treated with rituximab: Case report and review of the literature.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Ocrelizumab-induced colitis-critical review and case series from a Romanian cohort of MS patients.Frontiers in neurology · 2025Article
- Article
- Infliximab rescue therapy in a case of severe granulomatous colitis associated with rituximab use.BMJ case reports · 2024Article
- Gastrointestinal injury induced by immunomodulators: A review article.Therapeutic advances in gastroenterology · 2023Review
- Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?United European gastroenterology journal · 2022Review
- Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease: A case report and review of literature.World journal of clinical cases · 2022Article
- Cessation of methotrexate and a small intestinal resection provide a good clinical course for a patient with a jejunum perforation induced by a methotrexate-associated lymphoproliferative disorder: a case report.World journal of surgical oncology · 2021Article
- Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.Therapeutic advances in neurological disorders · 2021Review
- Natural-Derived Polysaccharides From Plants, Mushrooms, and Seaweeds for the Treatment of Inflammatory Bowel Disease.Frontiers in pharmacology · 2021Review
- Ocrelizumab-Induced Severe Colitis.Case reports in gastrointestinal medicine · 2020Article
- Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment.World journal of gastroenterology · 2019Review
- Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.Gastroenterology research · 2018Review
- Medication-associated gastrointestinal tract injury.Virchows Archiv : an international journal of pathology · 2017Review
- Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.Digestive diseases and sciences · 2016Article
- Proposed therapies in primary biliary cholangitis.Expert review of gastroenterology & hepatology · 2016Review
- Ulcerative colitis in a patient with non-small-cell lung cancer receiving bevacizumab.Investigational new drugs · 2015Article
- Novel therapeutic targets in primary biliary cirrhosis.Nature reviews. Gastroenterology & hepatology · 2015Review
- The PI3Kδ inhibitor idelalisib suppresses liver and lung cellular respiration.International journal of physiology, pathophysiology and pharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past, there has been considerable focus on a host of drugs and chemicals that may produce colonic toxicity. Now, a variety of new biological monoclonal antibody agents, usually administered by infusion, have appeared in the clinical realm over the last decade or so to treat different chronic inflammatory or malignant disorders.For some of these agents, adverse effects have been documented, including apparently new forms of immune-mediated inflammatory bowel disease. In some, only limited symptoms have been recorded, but in others, severe colitis with serious complications, such as bowel perforation has been recorded. In others, adverse effects may have a direct vascular or ischemic basis, while other intestinal effects may be related to a superimposed infection. Some new onset cases of ulcerative colitis or Crohn's disease may also be attributed to the same agents used to treat these diseases, or be responsible for disease exacerbation. Dramatic and well documented side effects have been observed with ipilimumab, a humanized monoclonal antibody developed to reduce and overcome cytotoxic T-lymphocyte antigen 4, a key negative feedback regulator of the T-cell anti-tumor response. This agent has frequently been used in the treatment of different malignancies, notably, malignant melanoma. Side effects with this agent occur in up to 40% and these are believed to be largely immune-mediated. One of these is a form of enterocolitis that may be severe, and occasionally, fatal. Other agents include rituximab (an anti-CD20 monoclonal antibody), bevacizumab (a monoclonal antibody against the vascular endothelial growth factor) and anti-tumor necrosis factor agents, including infliximab, adalimumab and etanercept.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.